Eslicarbazepine

DB14575ApprovedSmall molecule

Eslicarbazepine is an antiepileptic indicated as a monotherapy or adjunct therapy in the treatment of epilepsy. Eslicarbazepine is an anti-epileptic medication available commercially as eslicarbazepine acetate.

Chemical structure of Eslicarbazepine
Mechanism
Curator reviewed
Formula / weight
C15H14N2O2 · 254.2839 g/mol (avg)
Code names
BIA 2-194 · CGP-13751

Resolves to

Compound
UNIIS5VXA428R4CAS104746-04-5ChEMBLCHEMBL315985ChEBI174358
Clinical / RWD
RxNorm1482502ATCN03AF04
Structure
InChIKeyBMPDWHIDQYTSHX-AWEZNQCLSA-NSMILESNC(=O)N1C2=C(C[C@H](O)C3=C1C=CC=C3)C=CC=C2
Targets
Q99571P2RX4Q9UI33SCN11A

What you can answer from here — as of June 15, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
1,012Drug interactionsStructured to mechanism, not free text
Sign in
3Clinical trialsPhase, status and sponsor resolved per trial
Sign in
16Marketed productsAcross 1 country and 4 labellers
Sign in
1ATC codeIncluding every combination product, plus 18 drug categories
Sign in
13+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Eslicarbazepine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In